Medical Business Review
Anonymous User | Login

Sunridge Extends Chinese Distribution Deal With Beijing Vision

Published: 05-Feb-2010

Sunridge International (Sunridge) has extended the distribution agreement with Beijing Vision World Trading (Beijing Vision) on the Pneumatic Trabeculoplasty (PNT) treatment, for an additional four years.

Pneumatic Trabeculoplasty (PNT) is a two-minute, noninvasive, alternative treatment for glaucoma and ocular hypertension, which was developed and patented by Ophthalmic International (OI), a wholly-owned subsidiary of Sunridge.

Sunridge said that it has collaborated with Beijing Vision over the last three and a half years to complete the registration process for Pneumatic Trabeculoplasty, PNT, in China.

Richard Smith, CEO of Sunridge International, said: "The registration process for a medical device and treatment is strict in China. It is a long, expensive and tedious procedure. BV has worked over the last three and half years at a tremendous financial cost to its company to compete this process. They have performed several successful clinical trials at both private and state military hospitals as part of this effort. With approval expected in the very near future, BV is now concentrating on its marketing efforts.

“They have ordered and received delivery on 5 units with a number of disposable rings, to be placed in 5 major hospitals in Beijing. These hospitals will be used as models for the rest of the country. They are currently negotiating with a number of companies to act as sub distributors to expand distribution throughout all of China. BV is doing everything possible to ensure the marketing of PNT in China.

"This is an important event for OI. China is a major market for us, with millions of Glaucoma patients. The fact that a 'PNT' treatment lasts 3-4 months as a rule, with little or no side effects, makes it a very viable treatment for not only for the people of China, but for people everywhere. We expect that this will prove to be a very profitable market for OI."

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

IMCOR

LIMS and Laboratory Informatics Consultancy ...

Medical Device Developments

Reviews, Articles and Case Histories ...

Practical Patient Care

Current and Future Trends ...

Medical Imaging Technology

Information and Case Studies on Medical Imaging ...

TNO

Pharma Services: From Discovery to the Clinic ...

GOEBEL Instrumentelle Analytik

Complete Solutions in HPLC and UV/VIS Spectrophotometry ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Titanium Nitride (TiN)

Free white paper fact sheet on Tecvac's Titanium Nitride (TiN) product. ...

Nitron O

Free white paper fact sheet on Tecvac's Nitron O product. ...

Nitron MC

Free white paper fact sheet on Tecvac's Nitron MC product. ...

Nitron CA

Free white paper fact sheet on Tecvac's Nitron CA product. ...

Ion Implantation

Free white paper fact sheet on Tecvac's Ion Implantation product. ...

Diamolith (DLC)

Free white paper fact sheet on Tecvac's Diamolith (DLC) product ...

Related Companies

No items to display

Suppliers Product News

Amarna Therapeutics B.V. and TNO Announce SVac Research and Development Partnership

Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna's viral gene delivery platform SVac.

Free Newsletter Sign-up

Sign up, and we will send you a free Medical report on Cell Therapy – A New Lease of Life for the Heart’ from GlobalData worth $750

Please enter a valid email address